24,199 results on '"*RISPERIDONE"'
Search Results
2. Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders (tDCS&ASD)
3. The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS)
4. Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
5. Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
6. Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
7. CLOZAPINE Response in Biotype-1
8. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)
9. A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
10. Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis (CLOZ-AID)
11. Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
12. Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
13. Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (QUARTZ)
14. Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
15. Does Psilocybin Require Psychedelic Effects to Treat Depression? (PSI-RIS)
16. A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
17. Striatal Connectivity and Clinical Outcome in Psychosis
18. Long-term Antipsychotic Pediatric Safety Trial (LAPS)
19. Risperidone for the Treatment of Huntington's Disease Involuntary Movements
20. KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution (KF2022#3)
21. Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
22. An economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (ODT) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in Morocco.
23. Transcriptome analysis to explore the mechanism of downregulated TNIK influencing the effect of risperidone.
24. TREATMENT OF METHADONE PATIENTS WITH NEUROLEPTIC THERAPY AND HYPERPORLACTINEMIA.
25. Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®.
26. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments.
27. Co‐administration of sub‐effective doses of the constituents of Crocus sativus L. crocins with those of the antipsychotics clozapine and risperidone counteract memory deficits caused by blockade of the NMDA receptor in rats.
28. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
29. Incidence of Venous Thromboembolism Among Commonly Prescribed Second-Generation Antipsychotics.
30. Risperidone Pellets, Pycnogenol ® , and Glucomannan Gummy Formulation for Managing Weight Gain and ADHD in Autistic Children.
31. Quantification of Microsphere Drug Release by Fluorescence Imaging with the FRET System.
32. Comparison of antipsychotic drug use in children and adolescents in the Netherlands before and during the COVID-19 pandemic.
33. An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder.
34. Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration.
35. The use of psychotropic medications in autistic individuals (21 years and younger) in Western Australia: A preliminary investigation.
36. Growing evidence of pharmacotherapy effectiveness in managing attention-deficit/hyperactivity disorder in young children with or without autism spectrum disorder: a minireview.
37. Symptomatic remission and its associated factors among patients with schizophrenia on risperidone or olanzapine at Amanuel mental specialized hospital, Addis Ababa, Ethiopia.
38. Physiologically-Based Pharmacokinetic Modeling and In Vitro–In Vivo Correlation of TV-46000 (Risperidone LAI): Prediction from Dog to Human.
39. Assessing the Clinical Efficacy of Therapeutic Drug Monitoring for Risperidone and Paliperidone in Patients with Schizophrenia: Insights from a Clinical Data Warehouse.
40. Cerebral Computed Tomographic Findings in Schizophrenia: Relationship to Second-Generation Antipsychotics and Hyperprolactinemia.
41. Protective Effect of Hyperprolactinemia on Oxidative Stress in Patients with Psychotic Disorder on Atypical Antipsychotics Risperidone and Paliperidone: A Cross-Sectional Study.
42. COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.
43. Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database
44. Symptomatic remission and its associated factors among patients with schizophrenia on risperidone or olanzapine at Amanuel mental specialized hospital, Addis Ababa, Ethiopia
45. The antipsychotic potential of Salix Mucronata on ketamine-induced rats
46. Medications for Bipolar Disorder
47. Pharmacological Interventions and an Emerging Understanding of the Need to Consider Sex Differences in Treatment Planning
48. Neuroleptics
49. A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
50. Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT (SPACe2:STAR)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.